Get started
Author

Alain Thibault

Observed names: A Thibault, A. THIBAULT, A. Thibault, Thibault, Alain
Observed institutions: University of Iowa, University of Maryland, Baltimore, National Institutes of Health, Johnson & Johnson (United States), Mayo Clinic, The University of Texas MD Anderson Cancer Center, Regeneron (United States), University of Virginia Health System, Montreal General Hospital, Institut Jules Bordet, University of Rochester Medicine, Antwerp University Hospital, National Institute of Neurological Disorders and Stroke, National Cancer Institute, Ortho Clinical Diagnostics (United States), Argenx (Belgium), University of Virginia Cancer Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Janssen Research & Development (United States), University of Virginia, University of Rochester
OpenAlex ID: A5019216062
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
2001 · Judith E. Karp, Jeffrey E. Lancet, et al. · Blood · 443
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
1996 · A Thibault, D Samid, et al. · PubMed · 362
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
2003 · Jorge Cortes, Maher Albitar, et al. · Blood · 206
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
1994 · A Thibault, M R Cooper, et al. · PubMed · 157
Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome
2004 · Razelle Kurzrock, Maher Albitar, et al. · Journal of Clinical Oncology · 148
A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer
1998 · Alain Thibault, William D. Figg, et al. · Tumori Journal · 136
Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer
1994 · O. Sartor, M. Cooper, et al. · JNCI Journal of the National Cancer Institute · 135
Phase I study of phenylacetate administered twice daily to patients with cancer
1995 · Alain Thibault, Dvorit Samid, et al. · Cancer · 130
Risk Factors for the Development of Clostridium difficile -Associated Diarrhea During a Hospital Outbreak
1991 · Alain Thibault, Mark A. Miller, et al. · Infection Control and Hospital Epidemiology · 118
Lipid Metabolism as a Target for Brain Cancer Therapy: Synergistic Activity of Lovastatin and Sodium Phenylacetate Against Human Glioma Cells
1996 · Premakala Prasanna, Alain Thibault, et al. · Journal of Neurochemistry · 114
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
2013 · Karen Silence, Torsten Dreier, et al. · mAbs · 103
PDF
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
1995 · William D. Figg, Oliver Sartor, et al. · The American Journal of Medicine · 84
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
1995 · Nancy A. Dawson, Michael R. Cooper, et al. · Cancer · 74
PDF
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
2017 · Philippe Aftimos, Christian Rolfo, et al. · Clinical Cancer Research · 66
Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine
1995 · Stephen C. Piscitelli, Alain Thibault, et al. · The Journal of Clinical Pharmacology · 61
Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity.
2000 · D Samid, M Wells, et al. · PubMed · 56
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
2003 · Alex A Adjei, Gary A Croghan, et al. · PubMed · 52
Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.
2004 · Jeffrey E. Lancet, Jason Gotlib, et al. · Blood · 48
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer
1995 · William D. Figg, Alain Thibault, et al. · Cancer · 46
Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.
1994 · Z Ram, D Samid, et al. · PubMed · 44
A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors
2001 · Martine Piccart, Fabrice Branle, et al. · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · 41
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2015 · Anna Hultberg, Virginia Morello, et al. · Cancer Research · 40
PDF
Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.
1996 · S Shack, A Miller, et al. · PubMed · 32
Acute renal toxicity associated with suramin in the treatment of prostate cancer
1994 · William D. Figg, Michael R. Cooper, et al. · Cancer · 31
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells
1996 · Ronald Walls, Alain Thibault, et al. · The Prostate · 25
Works count: 73
Citation count: 2,919
H-index: 25
I10-index: 33
Year
Topic
Type